leflunomide has been researched along with Carcinoma, Hepatocellular in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with leflunomide, perindopril or curcumin alone abrogated the DEN-induced increased MVD as well as the elevated expression of VEGF, while only curcumin inhibited HIF-1α hepatic expression." | 5.40 | Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. ( Hamed, O; Kazem, A; Nasr, M; Selima, E, 2014) |
| "Treatment with leflunomide, perindopril or curcumin alone abrogated the DEN-induced increased MVD as well as the elevated expression of VEGF, while only curcumin inhibited HIF-1α hepatic expression." | 1.40 | Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. ( Hamed, O; Kazem, A; Nasr, M; Selima, E, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Hamid, NM | 1 |
| Abass, SA | 1 |
| Eldomany, RA | 1 |
| Abdel-Kareem, MA | 1 |
| Zakaria, S | 1 |
| Nasr, M | 1 |
| Selima, E | 1 |
| Hamed, O | 1 |
| Kazem, A | 1 |
| Casadio, F | 1 |
| Croci, S | 1 |
| D'Errico Grigioni, A | 1 |
| Corti, B | 1 |
| Grigioni, WF | 1 |
| Landuzzi, L | 1 |
| Lollini, PL | 1 |
3 other studies available for leflunomide and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats.
Topics: Alkylating Agents; Allyl Compounds; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Dieth | 2022 |
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antirheumatic Agents; Carc | 2014 |
Toward the definition of immunosuppressive regimens with antitumor activity.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Survival; Colore | 2005 |